TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).
Zefei Jiang, Jingfen Wang, Jiuwei Cui(Jilin University), Min Yan(Zhengzhou University), Jin Yang(Shanxi Medical University), Xinlan Liu(Yunnan Agricultural University), Tao Sun(Liaoning Cancer Hospital & Institute), Yuee Teng(First Hospital of China Medical University), Yongmei Yin(Nanjing Medical University), Xin Zhou(Qingdao University), Haibo Wang(The Third People's Hospital of Dalian City), Yongsheng Wang(Shandong Tumor Hospital), Lili Zhang(Guangxi Medical University), Xiaojia Wang(Wenzhou Medical University), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Gang Sun(Xinjiang Medical University), Tienan Yi(Xiangyang Central Hospital), Jun Qian(First Affiliated Hospital of Bengbu Medical College), Quchang Ouyang(Hunan Cancer Hospital)
Cited by 5
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k